Cargando…
Upregulation of SOX9 in osteosarcoma and its association with tumor progression and patients’ prognosis
OBJECTIVE: SOX9 plays an important role in bone formation and tumorigenesis. However, its involvement in osteosarcoma is still unclear. The aim of this study was to investigate the expression pattern and the clinical significance of SOX9 in human osteosarcoma. METHODS: SOX9 mRNA and protein expressi...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3829210/ https://www.ncbi.nlm.nih.gov/pubmed/24188461 http://dx.doi.org/10.1186/1746-1596-8-183 |
_version_ | 1782291332760338432 |
---|---|
author | Zhu, Haibo Tang, Jie Tang, Mingjie Cai, Haikang |
author_facet | Zhu, Haibo Tang, Jie Tang, Mingjie Cai, Haikang |
author_sort | Zhu, Haibo |
collection | PubMed |
description | OBJECTIVE: SOX9 plays an important role in bone formation and tumorigenesis. However, its involvement in osteosarcoma is still unclear. The aim of this study was to investigate the expression pattern and the clinical significance of SOX9 in human osteosarcoma. METHODS: SOX9 mRNA and protein expression levels were detected by RT-PCR and Western blot assays, respectively, using 30 pairs of osteosarcoma and noncancerous bone tissues. Then, immunohistochemistry was performed to analyze the association of SOX9 expression in 166 osteosarcoma tissues with clinicopathological factors or survival of patients. RESULTS: SOX9 expression at mRNA and protein levels were both significantly higher in osteosarcoma tissues than those in corresponding noncancerous bone tissues (both P < 0.001). Immunohistochemical staining indicated that SOX9 localized to the nucleus and high SOX9 expression was observed in 120 of 166 (72.3%) osteosarcoma specimens. In addition, high SOX9 expression was more frequently occurred in osteosarcoma tissues with advanced clinical stage (P = 0.02), positive distant metastasis (P = 0.008) and poor response to chemotherapy (P = 0.02). Osteosarcoma patients with high SOX9 expression had shorter overall survival and disease-free survival (both P < 0.001). Furthermore, the multivariate analysis confirmed that upregulation of SOX9 was an independent and significant prognostic factor to predict poor overall survival and disease-free survival (both P = 0.006). CONCLUSIONS: Our data show for the first time that SOX9 is upregulated in aggressive osteosarcoma tissues indicating that SOX9 may participate in the osteosarcoma progression. More importantly, SOX9 status is a useful prognostic factor for predicting the prognosis of osteosarcoma, suggesting that SOX9 may contribute to the optimization of clinical treatments for osteosarcoma patients. VIRTUAL SLIDES: The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1318085636110837. |
format | Online Article Text |
id | pubmed-3829210 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-38292102013-11-20 Upregulation of SOX9 in osteosarcoma and its association with tumor progression and patients’ prognosis Zhu, Haibo Tang, Jie Tang, Mingjie Cai, Haikang Diagn Pathol Research OBJECTIVE: SOX9 plays an important role in bone formation and tumorigenesis. However, its involvement in osteosarcoma is still unclear. The aim of this study was to investigate the expression pattern and the clinical significance of SOX9 in human osteosarcoma. METHODS: SOX9 mRNA and protein expression levels were detected by RT-PCR and Western blot assays, respectively, using 30 pairs of osteosarcoma and noncancerous bone tissues. Then, immunohistochemistry was performed to analyze the association of SOX9 expression in 166 osteosarcoma tissues with clinicopathological factors or survival of patients. RESULTS: SOX9 expression at mRNA and protein levels were both significantly higher in osteosarcoma tissues than those in corresponding noncancerous bone tissues (both P < 0.001). Immunohistochemical staining indicated that SOX9 localized to the nucleus and high SOX9 expression was observed in 120 of 166 (72.3%) osteosarcoma specimens. In addition, high SOX9 expression was more frequently occurred in osteosarcoma tissues with advanced clinical stage (P = 0.02), positive distant metastasis (P = 0.008) and poor response to chemotherapy (P = 0.02). Osteosarcoma patients with high SOX9 expression had shorter overall survival and disease-free survival (both P < 0.001). Furthermore, the multivariate analysis confirmed that upregulation of SOX9 was an independent and significant prognostic factor to predict poor overall survival and disease-free survival (both P = 0.006). CONCLUSIONS: Our data show for the first time that SOX9 is upregulated in aggressive osteosarcoma tissues indicating that SOX9 may participate in the osteosarcoma progression. More importantly, SOX9 status is a useful prognostic factor for predicting the prognosis of osteosarcoma, suggesting that SOX9 may contribute to the optimization of clinical treatments for osteosarcoma patients. VIRTUAL SLIDES: The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1318085636110837. BioMed Central 2013-11-04 /pmc/articles/PMC3829210/ /pubmed/24188461 http://dx.doi.org/10.1186/1746-1596-8-183 Text en Copyright © 2013 Zhu et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Zhu, Haibo Tang, Jie Tang, Mingjie Cai, Haikang Upregulation of SOX9 in osteosarcoma and its association with tumor progression and patients’ prognosis |
title | Upregulation of SOX9 in osteosarcoma and its association with tumor progression and patients’ prognosis |
title_full | Upregulation of SOX9 in osteosarcoma and its association with tumor progression and patients’ prognosis |
title_fullStr | Upregulation of SOX9 in osteosarcoma and its association with tumor progression and patients’ prognosis |
title_full_unstemmed | Upregulation of SOX9 in osteosarcoma and its association with tumor progression and patients’ prognosis |
title_short | Upregulation of SOX9 in osteosarcoma and its association with tumor progression and patients’ prognosis |
title_sort | upregulation of sox9 in osteosarcoma and its association with tumor progression and patients’ prognosis |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3829210/ https://www.ncbi.nlm.nih.gov/pubmed/24188461 http://dx.doi.org/10.1186/1746-1596-8-183 |
work_keys_str_mv | AT zhuhaibo upregulationofsox9inosteosarcomaanditsassociationwithtumorprogressionandpatientsprognosis AT tangjie upregulationofsox9inosteosarcomaanditsassociationwithtumorprogressionandpatientsprognosis AT tangmingjie upregulationofsox9inosteosarcomaanditsassociationwithtumorprogressionandpatientsprognosis AT caihaikang upregulationofsox9inosteosarcomaanditsassociationwithtumorprogressionandpatientsprognosis |